<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04876300</url>
  </required_header>
  <id_info>
    <org_study_id>000376</org_study_id>
    <nct_id>NCT04876300</nct_id>
  </id_info>
  <brief_title>MEDAM (Menopur Retrospective Data prograM)</brief_title>
  <acronym>MEDAM</acronym>
  <official_title>Predicting the Cumulative Live Birth Rate Further Ovarian Stimulation by Highly Purified Human Menotropin HP-hMG. A Multicentre, Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      French, non-interventional, retrospective, multicentric analysis of patients who have&#xD;
      undergone a controlled ovarian stimulation (COS) for in-vitro fertilization (IVF)/&#xD;
      intracytoplasmic sperm injection (ICSI). The main objective is to determine the cumulative&#xD;
      live birth rate with highly purified menotropin (HP-hMG) which is defined as the occurrence&#xD;
      of live birth per started COS, further to transfer of fresh and frozen embryos generated from&#xD;
      the same COS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative live birth rate (cLBR)</measure>
    <time_frame>At delivery</time_frame>
    <description>Defined as the occurence of live birth per started COS, further to transfer of fresh and frozen embryos generated from the same COS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial dose of Menotropin treatment per IVF cycle (IU)</measure>
    <time_frame>At Day 1 of Menotropin stimulation up to Day 20 of Menotropin stimulation during 2009 to 2016</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of Menotropin treatment per IVF cycle (IU)</measure>
    <time_frame>At Day 1 of Menotropin stimulation up to Day 20 of Menotropin stimulation during 2009 to 2016</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total days of Menotropin treatment (per IVF cycle)</measure>
    <time_frame>Up to end of the ovarian stimulation treatment (up to 20 days) during 2009 to 2016</time_frame>
    <description>Duration of treatment (in days) with Menotropin of patients will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose adjustment of Menotropin in IU</measure>
    <time_frame>At Day 1 of Menotropin stimulation up to Day 20 of Menotropin stimulation during 2009 to 2016</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of gonadotropin-releasing hormone (GnRH) protocols used for Luteinizing Hormone (LH) surge suppression (with in particular long and short agonist, and antagonist)</measure>
    <time_frame>At the day of the first GnRH administration during the ovarian stimulation treatment (up to 20 days) in 2009 to 2016</time_frame>
    <description>Gonadotropin-releasing hormone protocols with in particular long and short agonist, and antagonist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total days of LH surge suppression protocol</measure>
    <time_frame>From Day 1 up to the last day of GnRH analogues administration during 2009 to 2016</time_frame>
    <description>Gonadotropin-releasing hormone protocols with in particular long and short agonist, and antagonist.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">8126</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Menotropin Cohort</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study will take place.</description>
    <arm_group_label>Menotropin Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult women, fitting the inclusion/exclusion criteria, who were prescribed Menotropin&#xD;
        during 2009 to 2016 for COS in a treatment of infertility will be included in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patient undergoing a COS with HP-hMG for IVF/ICSI cycle from a French data registry&#xD;
        between 2009 to 2016&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ovulation inductions&#xD;
&#xD;
          -  Intra-uterine inseminations&#xD;
&#xD;
          -  Fertility preservations&#xD;
&#xD;
          -  Oocyte donations&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Adult females who underwent COS treatment with Menotropin during 2009 to 2016.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Compliance</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Global Clinical Compliance</last_name>
    <phone>+1 833-548-1402 (US/Canada)</phone>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Clinical Compliance</last_name>
    <phone>+1 862-286-5200 (outside US)</phone>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ferring investigational site</name>
      <address>
        <city>Bondy</city>
        <zip>93140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring investigational site</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring investigational site</name>
      <address>
        <city>Cr√©teil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring investigational site</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring investigational site</name>
      <address>
        <city>Lens</city>
        <zip>62190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring investigational site</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring investigational site</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring investigational site</name>
      <address>
        <city>Nice</city>
        <zip>06100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring investigational site</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ferring investigational site</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menotropin</keyword>
  <keyword>HP-hMG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

